# LCI-GI-APX-NIN-001: Nintedanib in Metastatic Appendiceal Carcinoma

> **NCT03287947** · PHASE2 · TERMINATED · sponsor: **Wake Forest University Health Sciences** · enrollment: 5 (actual)

## Conditions studied

- Appendix Cancer

## Interventions

- **DRUG:** nintedanib

## Key facts

- **NCT ID:** NCT03287947
- **Lead sponsor:** Wake Forest University Health Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-11-10
- **Primary completion:** 2019-09-03
- **Final completion:** 2019-10-27
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** Low enrollment
- **Last updated:** 2022-08-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03287947

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03287947, "LCI-GI-APX-NIN-001: Nintedanib in Metastatic Appendiceal Carcinoma". Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/clinical/NCT03287947. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*